Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Koshidacin B, a cyclic tetrapeptide, exhibits potent antiplasmodial activity, evidenced by its ability to inhibit Plasmodium falciparum strains FCR3 and K1 with IC50 values of 0.89 μM and 0.83 μM, respectively. It has been shown to effectively suppress malaria parasites in vivo and has potential applications in parasitic infection research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Koshidacin B, a cyclic tetrapeptide, exhibits potent antiplasmodial activity, evidenced by its ability to inhibit Plasmodium falciparum strains FCR3 and K1 with IC50 values of 0.89 μM and 0.83 μM, respectively. It has been shown to effectively suppress malaria parasites in vivo and has potential applications in parasitic infection research [1]. |
In vitro | Koshidacin B exhibits antiplasmodial properties, efficacious against both chloroquine-sensitive P. falciparum FCR3 and chloroquine-resistant P. falciparum K1 strains, presenting IC50 values of 0.89 μM and 0.83 μM after a 72-hour exposure, respectively [1]. Additionally, a 7-day exposure to Koshidacin B reveals cytotoxic effects on human MRC-5 cells with an IC50 of 14.7 μM [1]. |
In vivo | Koshidacin B, administered intraperitoneally at a dosage of 30 mg/kg once daily over a four-day period, exhibits in vivo antiplasmodial activity [1]. |
Molecular Weight | 544.64 |
Formula | C28H40N4O7 |
CAS No. | 2925302-01-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Koshidacin B 2925302-01-6 inhibitor inhibit